In this study, we establish that MYCN-amplified or MYCN-deregulated NB can be selectively targeted via combined CDK9/2 inhibition using CYC065, an orally bioavailable and clinically well-tolerated compound for which testing in the pediatric patient population is now warranted. Here, CDK9 is linked to neuroblastoma.